OTC
VRTX icon

Opera Trading Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Opera Trading Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,807
Closed -$348K – 161
2018
Q3 		$348K Buy
+1,807
New +$322K 0.07% 93
2016
Q3 		– Sell
-299
Closed -$26K – 128
2016
Q2 		$26K Sell
299
-675
-69% -$58.3K 0.01% 115
2016
Q1 		$77K Buy
974
+750
+335% +$67.8K 0.02% 112
2015
Q4 		$28K Buy
+224
New +$27K 0.01% 98

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Opera Trading Capital's VRTX Position: Q4 2018 in Review

Opera Trading Capital sold out of Vertex Pharmaceuticals (VRTX) in Q4 2018, closing a stake of 1,807 shares — an estimated $348K sold.

Opera Trading Capital first reported a position in VRTX in Q4 2015 and held it in 4 quarters. The position peaked at $348K in Q3 2018. 705 funds tracked by Wall St. Rank hold VRTX as of Q4 2018.

  • Opera Trading Capital reported no remaining Vertex Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Opera Trading Capital sold 1,807 Vertex Pharmaceuticals shares in Q4 2018, an estimated $348K.
  • Opera Trading Capital first reported a position in Vertex Pharmaceuticals in Q4 2015 and held it in 4 quarters.
  • Opera Trading Capital's Vertex Pharmaceuticals position peaked at $348K in Q3 2018.
  • 705 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2018.

Based on Opera Trading Capital's 13F filing for Q4 2018, filed 22 Jan 2019.